Antiviral response and resistance analysis of treatment-naïve HCV-infected patients receiving single and multiple doses of GS-9190.

about

Antiviral response and resistance analysis of treatment-naïve HCV-infected patients receiving single and multiple doses of GS-9190.

Item

http://www.wikidata.org/entity/Q40745083

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Antiviral response and resista ...... and multiple doses of GS-9190.

@en

type

Item

label

Antiviral response and resista ...... and multiple doses of GS-9190.

@en

prefLabel

Antiviral response and resista ...... and multiple doses of GS-9190.

@en

P1476

Antiviral response and resista ...... and multiple doses of GS-9190.

@en

P2093

C Hedskog

http://www.w3.org/2001/XMLSchema#string

D M Brainard

http://www.w3.org/2001/XMLSchema#string

E Svarovskaia

http://www.w3.org/2001/XMLSchema#string

H Mo

http://www.w3.org/2001/XMLSchema#string

I M Jacobson

http://www.w3.org/2001/XMLSchema#string

J G McHutchison

http://www.w3.org/2001/XMLSchema#string

M D Miller

http://www.w3.org/2001/XMLSchema#string

S-C Sun

http://www.w3.org/2001/XMLSchema#string

P2860

Selection and Characterization of Replicon Variants Dually Resistant to Thumb- and Palm-Binding Nonnucleoside Polymerase Inhibitors of the Hepatitis C Virus

Global epidemiology of hepatitis C virus infection

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

Sofosbuvir for previously untreated chronic hepatitis C infection

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.

Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.

Preexisting drug-resistance mutations reveal unique barriers to resistance for distinct antivirals

P304

644-651

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JVH.12536

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27004425

http://www.w3.org/2001/XMLSchema#string